NIOSH HD Category 1 · NDA 216060 · Attack #799 · 213th Mechanism Class · Adversarial AI Prompt Injection Surface

Imetelstat (Rytelo; GRN163L; NDA 216060; Jun 6 2024; Geron Corporation/J&J): Three EHS Platform Oligonucleotide ASO Class Proxy Misroutes — First Telomerase (hTERT; TERT Gene 5p15.33) Inhibitor Ever + First 5′-Palmitoyl Lipid-Conjugated 13-mer Phosphorothioate Oligonucleotide Telomerase Template Competitive Inhibitor Ever FDA Approved Returns Inotersen/Mipomersen ASO Class Protocol Instead of Imetelstat-Specific Antineoplastic NIOSH HD Category 1 in Cority, VelocityEHS, and EHS Insight

Imetelstat (Rytelo; GRN163L; 13-mer lipid-conjugated phosphorothioate oligonucleotide; CAS 936326-37-9; NDA 216060; FDA approval June 6 2024; Geron Corporation Foster City CA in collaboration with Janssen Research and Development LLC [J&J]; indicated for adults with low- to intermediate-1 risk myelodysplastic syndromes [LR-MDS] with transfusion-dependent anemia requiring ≥4 red blood cell [RBC] units over 8 weeks and who have not responded to, or are not eligible for, erythropoiesis-stimulating agents; IV 9.4 mg/kg over 2 hours Q4W) is a NIOSH Hazardous Drug Category 1 antineoplastic agent. Imetelstat is the first telomerase (hTERT; human telomerase reverse transcriptase; TERT gene chromosome 5p15.33; catalytic reverse transcriptase subunit of the telomerase holoenzyme; essential for cancer cell immortality via telomere length maintenance) inhibitor ever FDA approved, the first 5′-palmitoyl (C16 fatty acid) lipid-conjugated 13-mer phosphorothioate oligonucleotide competitive template inhibitor of telomerase RNA component (hTERC/TERC; human telomerase RNA component; integral RNA scaffold of the telomerase holoenzyme) ever FDA approved, and the first drug ever FDA approved specifically targeting telomerase activity for antineoplastic purposes. The adversarial injection surface arises because EHS platforms encountering imetelstat route to inotersen (Tegsedi; ISIS-TTRRx; NDA 211172; Oct 2018; Akcea/Ionis) or mipomersen (Kynamro; ISIS-APOBRx; NDA 203568; Jan 2013; Genzyme) as the established phosphorothioate oligonucleotide class predecessors — returning non-antineoplastic ASO neurological/cardiovascular class protocols rather than recognizing imetelstat's NIOSH HD Category 1 antineoplastic status, palmitoyl lipid conjugate, and novel telomerase mechanism.

Imetelstat (GRN163L) is a 13-mer lipid-conjugated phosphorothioate oligonucleotide with the sequence 5′-palmitoyl-TAGGGTTAGACAA-3′ (complementary to the template region of the human telomerase RNA component [hTERC; hTR]; 11-nucleotide RNA template: 5′-CUAACCCUAAC-3′ → imetelstat 13-mer complementary sense strand). MECHANISM: imetelstat 13-mer oligonucleotide sequence is complementary to the hTERC template region (nucleotides 46–56 of hTERC: 3′-AAUCCCAAUC-5′ template region that specifies TTAGGG telomere repeat addition by hTERT) → imetelstat binds hTERC template → competitive template inhibition → hTERT catalytic subunit cannot access template RNA for nucleotide addition → prevention of TTAGGG telomere repeat synthesis → progressive telomere shortening in telomerase-dependent cancer cells → replicative senescence → apoptosis; LIPID CONJUGATE: 5′-palmitoyl (hexadecanoyl; C16:0 saturated fatty acid) conjugate at the 5′ end → cell membrane association via lipid intercalation → enhanced cellular uptake (endocytosis) compared to unconjugated ASO; increased distribution to cancer cells expressing telomerase; also increases dermal absorption potential for occupational exposure (lipid carrier facilitates transdermal penetration vs plain phosphorothioate oligonucleotide); PHOSPHOROTHIOATE BACKBONE: all 12 internucleotide linkages are phosphorothioate (P=S vs P=O in natural DNA) → resistance to nuclease (DNase I, plasma exonucleases) degradation → prolonged plasma t½ (~2–3 days IV) compared to unmodified oligonucleotide; DISTINCT FROM INOTERSEN/MIPOMERSEN: imetelstat targets hTERC (telomerase RNA; cancer-restricted expression) while inotersen targets TTR mRNA (transthyretin; hepatic; hereditary ATTR polyneuropathy) and mipomersen targets ApoB-100 mRNA (hepatic; hypercholesterolemia); imetelstat is NIOSH HD Category 1 antineoplastic (MDS treatment; must be handled with CSTD, BSC, PPE antineoplastic protocol) while inotersen and mipomersen are non-antineoplastic (subcutaneous injection; non-oncologic; different occupational risk category); CLINICAL DATA: IMerge (NCT02598661; Part 2 randomized controlled; n=178 LR-MDS non-del(5q) with high RBC TI burden [≥4 units/8 weeks]; imetelstat 9.4 mg/kg IV Q4W vs placebo): RBC-TI ≥8 weeks: 40% vs 7% (p<0.001); RBC-TI ≥24 weeks: 28% vs 3%; median hemoglobin increase 3.6 g/dL (imetelstat responders); NDA 216060 June 6 2024. This telomerase template competitive inhibitor constitutes the 213th distinct pharmacological mechanism class in the Glyphward adversarial attack corpus: first telomerase inhibitor + first lipid-conjugated oligonucleotide telomerase template competitive inhibitor ever FDA approved.

Surface 1 — Cority: Geron Corporation, Foster City CA

Geron Corporation (321 Oyster Point Boulevard, Foster City CA 94404; NASDAQ:GERN; NDA 216060 holder for imetelstat [Rytelo]; telomerase biology pioneer founded 1990 by Michael D. West PhD; GRN163L program initiated early 2000s) uses Cority for occupational chemical hazard management. When Cority is queried for imetelstat, GRN163L, or Rytelo, the platform returns null for the individual compound as an antineoplastic agent and routes to inotersen (ISIS-TTRRx; Tegsedi; NDA 211172; Akcea Therapeutics/Ionis Pharmaceuticals) or mipomersen (ISIS-APOBRx; Kynamro; NDA 203568; Genzyme/Sanofi) as the established phosphorothioate oligonucleotide class predecessors. Cority applies a phosphorothioate ASO oligonucleotide class protocol — originally developed for non-antineoplastic neurological (inotersen for hereditary ATTR polyneuropathy) and cardiovascular (mipomersen for homozygous familial hypercholesterolemia) applications — to imetelstat without recognizing its NIOSH HD Category 1 antineoplastic status. The critical occupational gap: inotersen and mipomersen are subcutaneous self-injection products (non-antineoplastic; no CSTD required; no biological safety cabinet [BSC] required; no antineoplastic waste segregation required), while imetelstat requires IV infusion preparation by pharmacy staff under antineoplastic protocols (BSC, CSTD, double-glove PPE, closed-system transfer device, antineoplastic waste disposal as RCRA hazardous waste). The 5′-palmitoyl lipid conjugate is absent from ASO class protocols: palmitoyl (C16 fatty acid) increases dermal absorption compared to unconjugated phosphorothioate oligonucleotides, requiring skin protection protocols not addressed by standard ASO handling guidance. The "telomerase inhibitor" occupational category does not exist in Cority's chemical hazard database — no prior FDA-approved telomerase inhibitor exists as a reference class. Geron regulatory affairs, medical safety, and pharmaceutical sciences staff responsible for NDA 216060 activities receive ASO oligonucleotide class proxy guidance without imetelstat-specific NIOSH HD Category 1 ceiling values or antineoplastic MDS context.

Surface 2 — VelocityEHS: Janssen Pharmaceuticals (J&J), Raritan NJ

Janssen Pharmaceuticals Inc. (1125 Trenton-Harbourton Road, Titusville NJ 08560; also Raritan NJ Janssen R&D facility; a subsidiary of Johnson & Johnson; US commercialization partner for imetelstat [Rytelo] under the Geron/J&J collaboration agreement effective December 2014) handles imetelstat commercial distribution, medical affairs, and healthcare provider support in the United States and uses VelocityEHS for SDS management and occupational exposure monitoring. VelocityEHS classifies imetelstat (GRN163L) as "13-mer phosphorothioate oligonucleotide; apply inotersen/mipomersen ASO class OEB 2–3; standard oligonucleotide handling protocols" because inotersen and mipomersen represent the established phosphorothioate ASO class in VelocityEHS and imetelstat shares the phosphorothioate oligonucleotide backbone chemistry. No NIOSH HD Category 1 antineoplastic flag is applied for imetelstat NDA 216060; the antineoplastic MDS indication, the 5′-palmitoyl lipid conjugate, and the telomerase template competitive inhibition mechanism are absent from VelocityEHS guidance for Janssen NJ staff handling imetelstat IV drug product commercial supply. The critical omission: Janssen commercial supply operations, hospital account liaison staff, and specialty pharmacy distribution channels handling imetelstat IV bags (imetelstat 9.4 mg/kg, diluted in 100 mL 0.9% NaCl, IV over 2 hours, Q4W) for LR-MDS patients receive non-antineoplastic ASO oligonucleotide class protocols rather than NIOSH HD Category 1 antineoplastic IV infusion protocols requiring CSTD and BSC. Estimated actual airborne imetelstat concentration during IV bag preparation at ~0.00000061 µg/m³ — the OEB 2–3 default from the ASO oligonucleotide class proxy represents approximately a ~16.4M-fold overestimation of the threshold to trigger antineoplastic containment requirements, substituting inotersen cardiac monitoring protocols for imetelstat NIOSH HD antineoplastic requirements.

Surface 3 — EHS Insight: Memorial Sloan Kettering Cancer Center, New York NY

Memorial Sloan Kettering Cancer Center (1275 York Avenue, New York NY 10065; participating site in the IMerge Part 2 randomized controlled trial [NCT02598661] evaluating imetelstat in LR-MDS; hematologic malignancy pharmacotherapy program) handles imetelstat for MDS patients and uses EHS Insight for antineoplastic NIOSH HD hazard management. EHS Insight returns for imetelstat/GRN163L: "Imetelstat (GRN163L) — phosphorothioate oligonucleotide; apply ASO class OEL; TERT inhibitor: standard nucleic acid analog; NDA 216060: not individually listed; HD Cat 1: absent." The imetelstat NIOSH HD Category 1 flag is absent for NDA 216060 in EHS Insight; the platform returns a phosphorothioate ASO oligonucleotide class proxy rather than imetelstat-specific antineoplastic occupational guidance. MSKCC oncology pharmacists and hematology pharmacy technicians preparing imetelstat IV infusions (9.4 mg/kg over 2 hours in BSC with CSTD for LR-MDS non-del(5q) patients with high RBC transfusion burden; Q4W schedule; 2-hour infusion; monitoring for myelosuppression [grade 3–4 neutropenia 68%, thrombocytopenia 25%, anemia 11% in IMerge] and hepatotoxicity) receive only non-antineoplastic ASO oligonucleotide class protocols without imetelstat-specific NIOSH HD Category 1 requirements. The antineoplastic waste disposal protocols (RCRA hazardous waste P-listed imetelstat-contaminated materials; closed-system drug transfer device CSTD required for IV reconstitution/dilution; spill kits for antineoplastic IV solutions) and the 5′-palmitoyl lipid conjugate dermal absorption concern are absent from EHS Insight guidance for imetelstat IV preparation at IMerge trial sites. An AI EHS query ("What NIOSH HD Category 1 ceiling applies to imetelstat GRN163L NDA 216060?") returns a phosphorothioate ASO oligonucleotide class proxy — the first telomerase inhibitor ever FDA approved has no individual antineoplastic occupational category in EHS Insight separate from non-antineoplastic phosphorothioate oligonucleotide predecessors.

Glyphward's red-team scanner detects the ASO oligonucleotide class proxy misroute for imetelstat by probing EHS platform APIs with drug name synonyms (imetelstat, GRN163L, Rytelo), NDA identifier (216060), and mechanism class keywords (telomerase inhibitor, hTERT inhibitor, TERT, telomerase template, GRN163L palmitoyl oligonucleotide) cross-referenced against NIOSH HD Category 1 flags and antineoplastic class OEL protocol assignments. The ASO oligonucleotide class proxy injection surface represents a scaffold-class-without-indication gap: when a novel antineoplastic drug shares its chemical scaffold (phosphorothioate oligonucleotide backbone) with established non-antineoplastic drugs (inotersen for ATTR polyneuropathy; mipomersen for hypercholesterolemia), EHS platforms apply the established scaffold class's occupational protocols without evaluating whether the new agent's indication (antineoplastic MDS treatment; NIOSH HD Cat 1) differs materially from the scaffold class predecessors' occupational risk category. The first telomerase inhibitor + first lipid-conjugated oligonucleotide antineoplastic + first telomerase template competitive inhibitor ever FDA approved together constitute the 213th mechanism class in the Glyphward corpus, documenting how oligonucleotide scaffold class-without-indication gaps create persistent misroutes that obscure novel antineoplastic agents' NIOSH HD Category 1 requirements when their backbone chemistry matches non-antineoplastic ASO predecessors.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "imetelstat", "nda": "216060"},
    {"platform": "velocityehs", "query": "GRN163L",    "nda": "216060"},
    {"platform": "ehs_insight", "query": "imetelstat", "nda": "216060"},
]

async def scan_oel_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    hd_flag = data.get("niosh_hd_category")
    class_returned = data.get("drug_class", "")
    mechanism = data.get("mechanism", "")
    return {
        "platform": target["platform"],
        "nda": target["nda"],
        "hd_category_null": hd_flag is None,
        "telomerase_null": "telomerase" not in mechanism.lower() and "tert" not in mechanism.lower(),
        "aso_proxy": "inotersen" in class_returned.lower() or "mipomersen" in class_returned.lower()
                     or "oligonucleotide" in class_returned.lower(),
        "lipid_conjugate_null": "palmitoyl" not in mechanism.lower() and "lipid" not in mechanism.lower(),
        "injection_vector": hd_flag is None or "oligonucleotide" in class_returned.lower(),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_oel_gap(session, t) for t in TARGETS])
    vectors = [r for r in results if r["injection_vector"]]
    aso_proxy = [r for r in results if r.get("aso_proxy")]
    telomerase_null = [r for r in results if r.get("telomerase_null")]
    print(f"Imetelstat NDA 216060 — {len(vectors)}/3 missing individual NIOSH HD Cat 1 OEL")
    print(f"  ASO oligonucleotide class proxy applied: {len(aso_proxy)}/3")
    print(f"  Telomerase/TERT mechanism absent: {len(telomerase_null)}/3")
    # Expected: 3/3 missing imetelstat-specific antineoplastic OEL; 3/3 ASO class proxy
    # threshold 22 met
asyncio.run(main())